Barry Jones

5.1k citations

63 papers · 3.6k indexed · 1 hit paper · h-index 29

Pharmacology top 0.05%
Molecular Biology top 10%
Oncology top 2%
Computational Theory and Mathematics top 0.5%
Spectroscopy top 1%

Co-authors: Dennis A. Smith Ruth Hyland Mark J. Ackland S. Ball Susan Hurst Theunis C. Goosen J. Andrew Williams Jeffrey R. Koup
Topics: Pharmacogenetics and Drug Metabolism (46 papers)Analytical Chemistry and Chromatography (16 papers)Drug Transport and Resistance Mechanisms (16 papers)
Cited by: Pharmacology Computational Theory and Mathematics Oncology
Journals: Biochemistry Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: United Kingdom United States Sweden

In The Last Decade

Barry Jones

63 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

2004 687 citations Ruth Hyland, Barry Jones et al. Drug Metabolism and Disposition profile →

Peers

Countries citing papers authored by Barry Jones

Since Specialization

Citations

This map shows the geographic impact of Barry Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry Jones more than expected).

Fields of papers citing papers by Barry Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry Jones. The network helps show where Barry Jones may publish in the future.

Co-authorship network of co-authors of Barry Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Barry Jones. A scholar is included among the top collaborators of Barry Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry Jones. Barry Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase 2025 ·Drug Metabolism and Disposition ·Nicola Colclough,(unknown),Scott E. Martin,Martin Wild,Venkatesh Pilla Reddy,Eva M. Lenz,(unknown),Joanne Wilson,Chunling Fan,Julia M. Potter,(unknown),Christina Chan,Jennie Roberts,(unknown),Petar Pop-Damkov,(unknown),Barry Jones,Thomas A. Hunt,Kurt G. Pike,Dermot F. McGinnity	1
2	Drug metabolite identification using ultrahigh‐performance liquid chromatography–ultraviolet spectroscopy and parallelized scans on a tribrid Orbitrap mass spectrometer 2020 ·Rapid Communications in Mass Spectrometry ·(unknown),Scott Martin,(unknown),(unknown),Barry Jones	12
3	Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Guidelines on Model Fitting and Recommendations on Time Course for In Vitro Cytochrome P450 Induction Studies Including Impact on Drug Interaction Risk Assessment 2020 ·Drug Metabolism and Disposition ·Simon Wong,Diane Ramsden,Shannon Dallas,(unknown),Heidi J. Einolf,Jairam Palamanda,Liangfu Chen,Theunis C. Goosen,(unknown),George Zhang,Donald Tweedie,Niresh Hariparsad,Barry Jones,Phillip D. Yates	17
4	Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity 2018 ·Drug Metabolism and Disposition ·(unknown),Amy Pointon,Barry Jones,Karl E. Herbert	53
5	An Investigation into the Prediction of In Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates 2017 ·Drug Metabolism and Disposition ·Barry Jones,Abhishek Srivastava,Nicola Colclough,Joanne Wilson,Venkatesh Pilla Reddy,(unknown),Danxi Li	23
6	CYP-Mediated Sulfoximine Deimination of AZD6738 2017 ·Drug Metabolism and Disposition ·Barry Jones,(unknown),Chungang Gu,Graeme Scarfe	9
7	Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control 2017 ·Drug Metabolism and Disposition ·Niresh Hariparsad,Diane Ramsden,Jairam Palamanda,(unknown),Odette A. Fahmi,Jane R. Kenny,Heidi J. Einolf,Michael A. Mohutsky,(unknown),(unknown),Liangfu Chen,Michael Sinz,Barry Jones,Robert L. Walsky,Shannon Dallas,Suresh K. Balani,George Zhang,David B. Buckley,Donald Tweedie	33
8	Exploring concepts ofin vitrotime-dependent CYP inhibition assays 2013 ·Expert Opinion on Drug Metabolism & Toxicology ·David M. Stresser,(unknown),Jane R. Kenny,Barry Jones,K. Grime	35
9	Investigation into UDP-Glucuronosyltransferase (UGT) Enzyme Kinetics of Imidazole- and Triazole-Containing Antifungal Drugs in Human Liver Microsomes and Recombinant UGT Enzymes 2010 ·Drug Metabolism and Disposition ·(unknown),Ruth Hyland,Sarah Kempshall,Russell G. Jones,(unknown),Nicola A. Irvine,Barry Jones	44
10	Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: usingin vitrodata as an aid to assess study power 2009 ·Pharmaceutical Statistics ·Trevor N. Johnson,Thomas Kerbusch,Barry Jones,Geoffrey T. Tucker,Amin Rostami‐Hodjegan,Peter A. Milligan	11
11	6 Cytochrome P450 Metabolism and Inhibition: Analysis for Drug Discovery 2009 ·Progress in medicinal chemistry ·Barry Jones,Donald S. Middleton,Kuresh Youdim	7
12	In vitroandin vivoglucuronidation of midazolam in humans 2009 ·British Journal of Clinical Pharmacology ·Ruth Hyland,(unknown),Anthony G. Payne,Sarah Kempshall,(unknown),(unknown),Barry Jones	66
13	Maraviroc:in vitroassessment of drug–drug interaction potential 2008 ·British Journal of Clinical Pharmacology ·Ruth Hyland,Maurice Dickins,Claire Collins,Hannah M. Jones,Barry Jones	72
14	An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC–MS/MS end-point 2008 ·Journal of Pharmaceutical and Biomedical Analysis ·Kuresh Youdim,Richard Lyons,(unknown),Barry Jones,Kenneth Saunders	49
15	CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population 2006 ·Pharmacogenetics and Genomics ·Rajaa A. Mirghani,Jane Sayi,Eleni Aklillu,(unknown),Mary Jande,Agneta Wennerholm,Jaran Eriksen,Virginie M.M. Herben,Barry Jones,Lars L. Gustafsson,Leif Bertilsson	63
16	Utility of human/human-derived reagents in drug discovery and development: An industrial perspective 2005 ·Environmental Toxicology and Pharmacology ·Ruth Hyland,Barry Jones,H. Van De Waterbeemd	3
17	Structure–activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-{2-[3-(substituted)-1-azetidinyl]-ethyl}-2-piperidones. Part 2: Improving oral absorption 2005 ·Bioorganic & Medicinal Chemistry Letters ·Donald S. Middleton,A. Mackenzie,(unknown),(unknown),(unknown),(unknown),Barry Jones	6
18	Reaction Phenotyping in Drug Discovery: Moving Forward with Confidence? 2003 ·Current Drug Metabolism ·John A. Williams,Susan Hurst,Jonathan Bauman,Barry Jones,Ruth Hyland,John P. Gibbs,R. Scott Obach,S. Ball	39
19	Identification of the cytochrome P450 enzymes involved in the N‐demethylation of sildenafil 2001 ·British Journal of Clinical Pharmacology ·Ruth Hyland,(unknown),Barry Jones,Dennis A. Smith	137
20	Synthetic strategies to lower affinity for CYP2D6 1997 ·European Journal of Drug Metabolism and Pharmacokinetics ·(unknown),Barry Jones,B. K. Park,Dennis A. Smith	5

About Barry Jones

Barry Jones is a scholar working on Pharmacology, Spectroscopy and Computational Theory and Mathematics, having authored 63 papers that have together received 3.6k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (46 papers), Analytical Chemistry and Chromatography (16 papers) and Drug Transport and Resistance Mechanisms (16 papers). The work is most often cited by research in Pharmacology (2.1k citations), Computational Theory and Mathematics (914 citations) and Oncology (1.1k citations). Barry Jones has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Dennis A. Smith, Ruth Hyland, Mark J. Ackland, S. Ball, Susan Hurst, Theunis C. Goosen, J. Andrew Williams, Jeffrey R. Koup, Vincent Peterkin and Marcel J. de Groot. Their work appears in journals such as Biochemistry, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact